Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation

Keyphrases

• Absorption Feature 5%
• Adverse Event Monitoring 5%
• AUC0-24 5%
• Clinical Laboratory 5%
• Cmax 11%
• Cmin 16%
• Coefficient of Variation 5%
• Confidence Interval 5%
• Containment 5%
• Equivalence Limits 5%
• Extended Release 100%
• Extended-release Formulation 5%
• Fluctuation Index 11%
• Immediate Release 100%
• Immediate-release Formulation 5%
• Laboratory Evaluation 5%
• Least Mean Square 5%
• Monitoring Vital Signs 5%
• Multiple Dose 11%
• Occupancy Time 5%
• Once-daily 100%
• Partial AUC 5%
• Pharmacokinetic Equivalence 5%
• Pharmacokinetic Evaluation 100%
• Pharmacokinetic Parameters 11%
• Pharmacokinetic Profile 16%
• Pharmacokinetics 5%
• Plasma Exposure 11%
• Ratio of Means 5%
• Single Center 5%
• Steady State 100%
• Tmax 5%
• Tolerability 5%
• Topiramate 100%
• Twice Daily 11%
• Two-way Crossover 5%
• Vital Sign Measurement 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 5%
• Cmin 16%
• Normal Human 5%
• Pharmacokinetic Parameter 11%
• Pharmacokinetics 100%
• Tolerability 5%
• Topiramate 100%